Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00295893 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
121
Enrollment target
1
Study location

NCT00295893 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 121 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00295893, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
121 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy with or without trastuzumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer. PURPOSE: This randomized phase II trial is comparing two different regimens of combination chemotherapy given together with or without trastuzumab to see how well they work in treating patients with stage II or stage III breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Carboplatin
  • BIOLOGICAL Trastuzumab
  • DRUG cyclophosphamide
  • DRUG docetaxel
  • DRUG doxorubicin hydrochloride

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2005-09-27
Est. Completion 2026-08-11
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00295893

The ClinicalTrials.gov registry entry for NCT00295893 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT00295893 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00295893 about?

NCT00295893 is a clinical study titled "Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block tumor g...

What is the current status of trial NCT00295893?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2005-09-27. Estimated completion is 2026-08-11.

What conditions does trial NCT00295893 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00295893?

The interventions under investigation include: Carboplatin (DRUG), Trastuzumab (BIOLOGICAL), cyclophosphamide (DRUG), docetaxel (DRUG), doxorubicin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00295893?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00295893 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.